USANA Health Sciences Reports Third Quarter Results
SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021.
Key Financial & Operating Highlights
- Third quarter net sales were $274.4 million as compared with $298.5 million during the third quarter of the prior year.
- Third quarter diluted EPS were $1.36 versus $1.44 during the third quarter of 2020.
- Reiterates fiscal 2021 net sales and diluted EPS outlook, which was provided on September 16, 2021.
- Company expects to generate approximately $130 million of free cash flow in fiscal 2021.
Q3 2021 Financial Performance
|
Consolidated Results |
||
|
Net Sales |
$274.4 million |
|
|
Diluted EPS |
$1.36 |
|
|
Active Customers |
576,000 |
|
“As we indicated a month ago, the operating environment remains challenging across several of our key markets due, in great part, to disruptions and lockdowns related to the COVID-19 pandemic,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Additionally, the year-over-year comparison was difficult given the significant short-term sales program that we offered in the prior year quarter. Notwithstanding these challenges, we continue to execute our growth strategy, which is centered on generating sustainable customer growth.”
Q3 2021 Regional Results:
|
Asia Pacific Region |
||
|
Net Sales |
$220.9 million |
|
|
Active Customers |
443,000 |
|
|
Asia Pacific Sub-Regions |
||
|
Greater China |
||
|
Net Sales |
$123.2 million |
|
|
Active Customers |
246,000 |
|
|
North Asia |
||
|
Net Sales |
$33.1 million |
|
|
Active Customers |
63,000 |
|
|
Southeast Asia Pacific |
||
|
Net Sales |
$64.6 million |
|
|
Active Customers |
134,000 |
|
|
Americas and Europe Region |
||
|
Net Sales |
$53.5 million |
|
|
Active Customers |
133,000 |
|
Mr. Guest added, “We made progress on several strategic initiatives during the quarter. Enhancing the overall shopping experience for our customers remains a high priority, and to that end, we rolled out additional features and functionality within our China shopping app, as well as a new web-based shopping cart in China. Although our introduction of certain new products has been delayed until 2022, we are actively engaged in bringing new and innovative products to market. Overall, we remain confident that the successful execution of our strategy will deliver long-term, sustainable growth.”
Balance Sheet and Share Repurchase Activity
The Company ended the quarter with $249 million in cash and cash equivalents and no debt after repurchasing 523,000 shares for $50 million. Diluted shares outstanding totaled 20.2 million during the third quarter of 2021. As of October 2, 2021, the Company had approximately $137 million remaining under the share repurchase authorization, following the Company’s increase of the repurchase authorization on September 16, 2021.
Fiscal 2021 Outlook
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2021, which was provided on September 16, 2021.
|
Fiscal Year 2021 Outlook |
|
|
|
Range |
|
Consolidated Net Sales |
$1.18 - $1.20 billion |
|
Diluted EPS |
$5.80 - $6.00 |
The Company maintains a 52/53-week fiscal year. Fiscal 2020 was a 53-week year and included one additional week of sales in the fourth quarter of 2020 compared to Fiscal 2021.
Doug Hekking, Chief Financial Officer, said, “We are reiterating our outlook for fiscal 2021 with third quarter results coming in just ahead of the projections we provided on September 16th. Our outlook incorporates ongoing investments required to achieve long-term growth objectives that may impact near-term operating margins.”
Management Commentary Document and Conference Call
For more information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, October 27, 2021 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results. Free cash flow is a non-GAAP financial measure that we believe provides investors an additional perspective on cash flow from operating activities in excess of amounts required for reinvestment. We believe it provides a measure of our ability to fund various discretionary business initiatives, including acquisitions and share repurchase. Free cash flow is calculated by subtracting net capital expenditures from net cash provided by operating activities.
About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.
| USANA Health Sciences, Inc. | |||||||||||||||
| Consolidated Statements of Operations | |||||||||||||||
| (In thousands, except per share data) | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
Quarter Ended |
|
Nine Months Ended |
|||||||||||||
|
2-Oct-21 |
|
26-Sep-20 |
|
2-Oct-21 |
|
26-Sep-20 |
|||||||||
| Net sales |
$ |
274,352 |
|
$ |
298,513 |
|
$ |
919,165 |
$ |
824,123 |
|
||||
| Cost of sales |
|
50,715 |
|
|
56,358 |
|
|
165,380 |
|
150,091 |
|
||||
| Gross profit |
|
223,637 |
|
|
242,155 |
|
|
753,785 |
|
674,032 |
|
||||
| Operating expenses: | |||||||||||||||
| Associate incentives |
|
116,222 |
|
|
131,144 |
|
|
404,580 |
|
358,065 |
|
||||
| Selling, general and administrative |
|
66,645 |
|
|
65,656 |
|
|
210,518 |
|
192,014 |
|
||||
| Earnings from operations |
|
40,770 |
|
|
45,355 |
|
|
138,687 |
|
123,953 |
|
||||
| Other income (expense), net |
|
(420 |
) |
|
(1,080 |
) |
|
309 |
|
(536 |
) |
||||
| Earnings before income taxes |
|
40,350 |
|
|
44,275 |
|
|
138,996 |
|
123,417 |
|
||||
| Income taxes |
|
13,020 |
|
|
13,769 |
|
|
42,811 |
|
38,382 |
|
||||
| NET EARNINGS |
$ |
27,330 |
|
$ |
30,506 |
|
$ |
96,185 |
$ |
85,035 |
|
||||
| Earnings per share - diluted |
$ |
1.36 |
|
$ |
1.44 |
|
$ |
4.68 |
$ |
4.00 |
|
||||
| Weighted average shares outstanding - diluted |
|
20,156 |
|
|
21,170 |
|
|
20,566 |
|
21,283 |
|
||||
| USANA Health Sciences, Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| (In thousands) | ||||||
| (Unaudited) | ||||||
|
As of |
As of |
|||||
|
2-Oct-21 |
2-Jan-21 |
|||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash and cash equivalents |
$ |
248,695 |
$ |
311,917 |
||
| Inventories |
|
96,316 |
|
90,224 |
||
| Prepaid expenses and other current assets |
|
23,414 |
|
23,145 |
||
| Total current assets |
|
368,425 |
|
425,286 |
||
| Property and equipment, net |
|
100,957 |
|
100,445 |
||
| Goodwill |
|
17,510 |
|
17,367 |
||
| Intangible assets, net |
|
30,312 |
|
30,796 |
||
| Deferred tax assets |
|
5,465 |
|
4,640 |
||
| Other assets |
|
56,277 |
|
62,353 |
||
| Total assets |
$ |
578,946 |
$ |
640,887 |
||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities | ||||||
| Accounts payable |
$ |
13,706 |
$ |
18,195 |
||
| Other current liabilities |
|
144,258 |
|
149,878 |
||
| Total current liabilities |
|
157,964 |
|
168,073 |
||
| Deferred tax liabilities |
|
7,840 |
|
12,009 |
||
| Other long-term liabilities |
|
14,063 |
|
19,155 |
||
| Stockholders' equity |
|
399,079 |
|
441,650 |
||
| Total liabilities and stockholders' equity |
$ |
578,946 |
$ |
640,887 |
||
| USANA Health Sciences, Inc. | |||||||||||||||||||||||||
| Sales by Region | |||||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||||
| Quarter Ended | |||||||||||||||||||||||||
| October 2, 2021 | September 26, 2020 | Change from prior year | Currency impact on sales |
% change excluding currency impact |
|||||||||||||||||||||
| Asia Pacific | |||||||||||||||||||||||||
| Greater China |
$ |
123,235 |
44.9 |
% |
$ |
136,013 |
45.5 |
% |
$ |
(12,778 |
) |
(9.4 |
%) |
$ |
7,457 |
(14.9 |
%) |
||||||||
| Southeast Asia Pacific |
|
64,570 |
23.5 |
% |
|
76,313 |
25.6 |
% |
|
(11,743 |
) |
(15.4 |
%) |
|
85 |
(15.5 |
%) |
||||||||
| North Asia |
|
33,068 |
12.1 |
% |
|
28,969 |
9.7 |
% |
|
4,099 |
|
14.1 |
% |
|
770 |
11.5 |
% |
||||||||
| Asia Pacific Total |
|
220,873 |
80.5 |
% |
|
241,295 |
80.8 |
% |
|
(20,422 |
) |
(8.5 |
%) |
|
8,312 |
(11.9 |
%) |
||||||||
| Americas and Europe |
|
53,479 |
19.5 |
% |
|
57,218 |
19.2 |
% |
|
(3,739 |
) |
(6.5 |
%) |
|
1,570 |
(9.3 |
%) |
||||||||
|
$ |
274,352 |
100.0 |
% |
$ |
298,513 |
100.0 |
% |
$ |
(24,161 |
) |
(8.1 |
%) |
$ |
9,882 |
(11.4 |
%) |
|||||||||
| Active Associates by Region(1) | ||||||||
| (unaudited) | ||||||||
| As of | ||||||||
| October 2, 2021 | September 26, 2020 | |||||||
| Asia Pacific | ||||||||
| Greater China |
81,000 |
29.8% |
91,000 |
29.1% |
||||
| Southeast Asia Pacific |
90,000 |
33.1% |
113,000 |
36.1% |
||||
| North Asia |
39,000 |
14.3% |
39,000 |
12.4% |
||||
| Asia Pacific Total |
210,000 |
77.2% |
243,000 |
77.6% |
||||
| Americas and Europe |
62,000 |
22.8% |
70,000 |
22.4% |
||||
|
272,000 |
100.0% |
313,000 |
100.0% |
|||||
| Active Preferred Customers by Region (2) | ||||||||
| (unaudited) | ||||||||
|
As of |
||||||||
|
October 2, 2021 |
September 26, 2020 |
|||||||
| Asia Pacific | ||||||||
| Greater China |
165,000 |
54.3% |
193,000 |
57.3% |
||||
| Southeast Asia Pacific |
44,000 |
14.4% |
45,000 |
13.4% |
||||
| North Asia |
24,000 |
7.9% |
21,000 |
6.2% |
||||
| Asia Pacific Total |
233,000 |
76.6% |
259,000 |
76.9% |
||||
| Americas and Europe |
71,000 |
23.4% |
78,000 |
23.1% |
||||
|
304,000 |
100.0% |
337,000 |
100.0% |
|||||
| (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale. | ||||||||||||||||||
| (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006199/en/
Investor contact:
Patrique Richards
Investor Relations
(801) 954-7961
investor.relations@usanainc.com
Media contact:
Dan Macuga
Public Relations
(801) 954-7280
Source: USANA Health Sciences, Inc.
Released October 26, 2021